Mitsubishi UFJ Asset Management Co. Ltd. Acquires 16,425 Shares of Illumina, Inc. $ILMN

Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 11.9% during the 4th quarter, Holdings Channel reports. The firm owned 154,596 shares of the life sciences company’s stock after buying an additional 16,425 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Illumina were worth $20,770,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Capital World Investors grew its stake in shares of Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. State Street Corp grew its stake in shares of Illumina by 6.8% in the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Illumina by 3.1% in the third quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock worth $315,915,000 after purchasing an additional 102,147 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Illumina by 1.9% in the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after purchasing an additional 35,167 shares during the last quarter. Finally, ARK Investment Management LLC grew its stake in shares of Illumina by 25.7% in the third quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company’s stock worth $139,405,000 after purchasing an additional 299,801 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ILMN shares. Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Citigroup lifted their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. JPMorgan Chase & Co. lifted their price objective on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Guggenheim lifted their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Canaccord Genuity Group cut their price objective on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $131.06.

Illumina Stock Performance

Illumina stock opened at $141.88 on Friday. The stock’s 50 day simple moving average is $126.86 and its two-hundred day simple moving average is $127.86. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a market cap of $21.47 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.35 and a beta of 1.42. Illumina, Inc. has a fifty-two week low of $75.24 and a fifty-two week high of $155.53.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the business earned $0.97 earnings per share. The business’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.